Do the benefits of subcutaneous immunoglobulin therapy for secondary hypogammaglobulinemia in ANCA vasculitis extend beyond infection prevention?

Kidney Int. 2022 Aug;102(2):444-445. doi: 10.1016/j.kint.2022.04.035.
No abstract available

Publication types

  • Letter

MeSH terms

  • Agammaglobulinemia* / therapy
  • Antibodies, Antineutrophil Cytoplasmic
  • Humans
  • Immunization, Passive*
  • Rituximab
  • Vasculitis*

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Rituximab